Schering-Plough announces strong results with Intervet

Schering-Plough has announced its financial results for the final quarter of 2007, with animal health sales totalling more than $507 million (£257 million) over the three-month period.

It has announced $217 million of that sum related to Intervet, which it acquired in November 2007.

This purchase, it noted, allowed the company to expand its vaccine product business, making Schering-Plough’s animal health business one of the leading firms in the vaccine segment.

Fred Hassan, chairman and chief executive officer of Schering-Plough, commented: “Today, we are a much stronger and more diverse company than ever before and we are better positioned to deal with the new challenges confronting us in 2008.”

Earlier this year, Intervet commented that together with Schering-Plough, it would be a “world market leader” in animal health vaccines.

It suggested its acquisition by the larger company will bring together complementary services such as pharmaceuticals and biologicals.